CY1113051T1 - Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α - Google Patents

Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α

Info

Publication number
CY1113051T1
CY1113051T1 CY20121100736T CY121100736T CY1113051T1 CY 1113051 T1 CY1113051 T1 CY 1113051T1 CY 20121100736 T CY20121100736 T CY 20121100736T CY 121100736 T CY121100736 T CY 121100736T CY 1113051 T1 CY1113051 T1 CY 1113051T1
Authority
CY
Cyprus
Prior art keywords
lactic
aids
deficiency
therapeutic treatment
preparations
Prior art date
Application number
CY20121100736T
Other languages
English (en)
Inventor
Richard Selden
Marianne Borowski
Carol M Kinoshita
Douglas A Treco
Melanie D Williams
Thomas J Schuetz
Peter Francis Daniel
Original Assignee
Shire Human Genetic Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23012821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113051(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies, Inc. filed Critical Shire Human Genetic Therapies, Inc.
Publication of CY1113051T1 publication Critical patent/CY1113051T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Η εφεύρεση προβλέπει εξαιρετικής καθαρότητας α-Gal Α και διάφορες μεθόδους για τον καθαρισμό αυτής· παρασκευάσματα α-Gal Α με αλλαγμένο φορτίο και μεθόδους για την κατασκευή αυτών των παρασκευασμάτων· σκευάσματα α-Gal Α με παρατεταμένη διάρκεια ημιζωής σε θηλαστικά ξενιστές και μεθόδους για την κατασκευή αυτών· καθώς και μεθόδους και δοσολογίες για τη χορήγηση παρασκευάσματος α-Gal Α σε κάποιο άτομο.
CY20121100736T 1999-03-11 2012-08-10 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α CY1113051T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/266,014 US6458574B1 (en) 1996-09-12 1999-03-11 Treatment of a α-galactosidase a deficiency
EP10152432A EP2186902B1 (en) 1999-03-11 2000-03-09 Medical preparations for the treatment of alpha-galactosidase a deficiency

Publications (1)

Publication Number Publication Date
CY1113051T1 true CY1113051T1 (el) 2016-04-13

Family

ID=23012821

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20081100521T CY1107951T1 (el) 1999-03-11 2008-05-20 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α
CY20121100736T CY1113051T1 (el) 1999-03-11 2012-08-10 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α
CY20171100801T CY1119369T1 (el) 1999-03-11 2017-07-26 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20081100521T CY1107951T1 (el) 1999-03-11 2008-05-20 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171100801T CY1119369T1 (el) 1999-03-11 2017-07-26 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α

Country Status (22)

Country Link
US (4) US6458574B1 (el)
EP (6) EP2186902B1 (el)
JP (6) JP2002538183A (el)
KR (2) KR100892334B1 (el)
CN (4) CN103585621B (el)
AT (1) ATE386808T1 (el)
AU (1) AU3519400A (el)
CA (3) CA2365923A1 (el)
CY (3) CY1107951T1 (el)
DE (1) DE60038104T2 (el)
DK (3) DK2314699T3 (el)
ES (3) ES2634317T3 (el)
HK (3) HK1043386B (el)
HU (1) HU228743B1 (el)
IL (2) IL145381A0 (el)
MX (1) MXPA01009222A (el)
NO (2) NO329689B1 (el)
NZ (1) NZ514077A (el)
PL (1) PL210833B1 (el)
PT (3) PT1163349E (el)
RU (1) RU2248213C2 (el)
WO (1) WO2000053730A2 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) * 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
ES2367257T3 (es) * 2002-04-25 2011-10-31 Shire Human Genetic Therapies, Inc. Tratamiento de deficit de alfa-galactosidasa a.
US20060018882A1 (en) * 2004-06-21 2006-01-26 Kaemmerer William F Medical devices and methods for delivering compositions to cells
PT2444102E (pt) * 2003-01-31 2015-09-17 Sinai School Medicine Terapia combinada para o tratamento de distúrbios de deficiência proteica
US7422310B2 (en) * 2003-04-25 2008-09-09 Hewlett-Packard Development Company, L.P. Methods and apparatus for selecting image enhancement techniques
US20100196345A1 (en) * 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
JP4914224B2 (ja) 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CN1308444C (zh) * 2005-04-15 2007-04-04 中国人民解放军军事医学科学院野战输血研究所 基因重组α-半乳糖苷酶大批量发酵液的纯化方法
MX2007014470A (es) 2005-05-17 2008-02-06 Amicus Therapeutics Inc Metodo para el tratamiento de enfermedad de pompe usando derivados de 1-desoxinojirimicina.
US7935336B2 (en) 2005-11-18 2011-05-03 Tokyo Metropolitan Organization For Medical Research Highly functional enzyme having α-galactosidase activity
WO2007086067A1 (en) * 2006-01-30 2007-08-02 Diagnostic Technologies Ltd. Method for monitoring tocolytic treatment
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
EP2150608B1 (en) * 2007-05-07 2017-11-29 Protalix Ltd. Large scale disposable bioreactor
WO2009032171A1 (en) * 2007-08-29 2009-03-12 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
AU2009244148B2 (en) * 2008-05-07 2014-10-09 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP3075386B1 (en) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
NZ623294A (en) * 2010-03-02 2015-10-30 Protalix Ltd Stabilized alpha-galactosidase and uses thereof
US20110293585A1 (en) * 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
JP6138683B2 (ja) 2010-07-08 2017-05-31 バクスアルタ ゲーエムベーハー 細胞培養による組換え型adamts13産生方法
EP2627349B1 (en) 2010-10-15 2016-02-03 The Trustees of Columbia University in the City of New York Obesity-related genes and their proteins and uses thereof
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9376506B2 (en) * 2011-03-04 2016-06-28 Glytech, Inc. Method for producing sialic-acid-containing sugar chain
BR112013031553A2 (pt) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
JP6236406B2 (ja) 2012-03-07 2017-11-22 アミカス セラピューティックス インコーポレイテッド ポンペ病の処置のための高濃度α−グルコシダーゼ組成物
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
PT2830662T (pt) 2012-03-29 2018-11-29 Univ Columbia Métodos para tratamento de distúrbios de perda de pelo
EP2874648A4 (en) 2012-07-17 2015-12-30 Amicus Therapeutics Inc CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Jcrファーマ株式会社 組換えヒトα−ガラクトシダーゼAの製造方法
WO2014120900A1 (en) * 2013-01-31 2014-08-07 Icahn School Of Medicine At Mount Sinai Enhanced therapeutic regimens for treating fabry disease
ES2708562T3 (es) 2013-03-14 2019-04-10 Translate Bio Inc Evaluación cuantitativa de la eficacidad de tapa de ARN mensajero
ES2680595T3 (es) 2013-03-14 2018-09-10 Translate Bio, Inc. Evaluación cuantitativa para eficacia de ARN mensajero para tapar
TW202332774A (zh) 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
BR112016019893B1 (pt) 2014-03-05 2023-02-14 Ultragenyx Pharmaceutical Inc Composição
RS65066B1 (sr) 2014-09-30 2024-02-29 Amicus Therapeutics Inc Visoko potentna kisela alfa-glukozidaza sa pojačanim ugljenim hidratima
LT3237621T (lt) 2014-12-22 2023-09-25 Codexis, Inc. Žmogaus alfa-galaktozidazės variantai
BR112017013423B1 (pt) * 2014-12-22 2023-04-11 Genzyme Corporation Métodos para cultivo de célula de mamífero
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017044807A2 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
IL299470A (en) 2015-12-30 2023-02-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
SG11201808592PA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Method for selection of high m6p recombinant proteins
KR20240001291A (ko) 2016-03-30 2024-01-03 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
MX2019004487A (es) * 2016-10-20 2020-02-07 Sangamo Therapeutics Inc Metodos y composiciones para el tratamiento de la enfermedad de fabry.
TW201829770A (zh) * 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
US11708569B2 (en) * 2018-08-29 2023-07-25 University Of Copenhagen Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid
CA3123598A1 (en) 2018-12-20 2020-06-25 Codexis, Inc. Human alpha-galactosidase variants
JP2022540632A (ja) 2019-07-09 2022-09-16 ジェネトン 糖原病(gsd)の処置

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5322158B2 (el) * 1974-05-02 1978-07-06
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
DE3580384D1 (de) 1984-04-09 1990-12-13 Toyo Boseki Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle.
US4764376A (en) 1984-06-18 1988-08-16 Eli Lilly And Company Method of inhibiting aromatase
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
KR0159107B1 (ko) * 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
KR920701436A (ko) * 1989-09-05 1992-08-11 피터 터베이 재조합 생성물
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
JP3230056B2 (ja) 1991-07-02 2001-11-19 インヘイル・インコーポレーテッド 薬剤のエーロゾル化服用量を形成する装置
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5858751A (en) 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
DK0641192T3 (da) 1992-05-18 1998-03-02 Minnesota Mining & Mfg Anordning til transmucosal lægemiddelafgivelse
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US5770405A (en) * 1993-09-23 1998-06-23 New England Biolabs, Inc. Isolation and composition of novel glycosidases
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en) 1993-12-28 1998-12-01 Becton Dickinson And Company Molecules for iontophoretic delivery
US5789247A (en) 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
JPH10513057A (ja) * 1995-01-30 1998-12-15 ニューヨーク・ブラッド・センター・インコーポレイテッド 組換えα−ガラクトシダーゼ酵素
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
EP0935651B1 (en) 1996-09-13 2004-12-29 Transkaryotic Therapies, Inc. THERAPY FOR alpha-GALACTOSIDASE A DEFICIENCY
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL125423A (en) * 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes

Also Published As

Publication number Publication date
EP2186902B1 (en) 2012-05-23
EP3231871A1 (en) 2017-10-18
DE60038104D1 (de) 2008-04-03
EP2314699B1 (en) 2017-05-31
CN106110309A (zh) 2016-11-16
MXPA01009222A (es) 2002-06-04
JP5615648B2 (ja) 2014-10-29
WO2000053730A3 (en) 2001-03-15
JP6626071B2 (ja) 2019-12-25
KR20070090277A (ko) 2007-09-05
CA2833396A1 (en) 2000-09-14
DE60038104T2 (de) 2009-02-12
JP6081980B2 (ja) 2017-02-15
IL145381A (en) 2009-12-24
US20110280856A1 (en) 2011-11-17
JP2002538183A (ja) 2002-11-12
ES2391221T3 (es) 2012-11-22
WO2000053730A9 (en) 2001-10-11
PL350658A1 (en) 2003-01-27
CN1354796A (zh) 2002-06-19
CN101219213A (zh) 2008-07-16
EP1820862A3 (en) 2007-10-31
US20030077806A1 (en) 2003-04-24
HK1043386A1 (en) 2002-09-13
EP2186902A3 (en) 2010-09-01
PT2186902E (pt) 2012-08-28
US6458574B1 (en) 2002-10-01
IL145381A0 (en) 2002-06-30
PT1163349E (pt) 2008-05-19
NO20014415D0 (no) 2001-09-11
CY1119369T1 (el) 2018-02-14
DK2314699T3 (en) 2017-08-07
CN100417727C (zh) 2008-09-10
KR100961740B1 (ko) 2010-06-07
WO2000053730A2 (en) 2000-09-14
HK1043386B (zh) 2008-06-13
KR100892334B1 (ko) 2009-04-08
HUP0200467A3 (en) 2006-06-28
AU3519400A (en) 2000-09-28
HK1143833A1 (en) 2011-01-14
JP5899169B2 (ja) 2016-04-06
NO329689B1 (no) 2010-11-29
JP2011037867A (ja) 2011-02-24
EP2287319A1 (en) 2011-02-23
JP6346236B2 (ja) 2018-06-20
CA3012663A1 (en) 2000-09-14
NO20101493L (no) 2001-11-12
KR20020021371A (ko) 2002-03-20
ES2634317T3 (es) 2017-09-27
US20030113894A1 (en) 2003-06-19
HU228743B1 (en) 2013-05-28
HK1245320A1 (zh) 2018-08-24
EP2314699A1 (en) 2011-04-27
CN103585621A (zh) 2014-02-19
ATE386808T1 (de) 2008-03-15
DK2186902T3 (da) 2012-09-03
JP2017014279A (ja) 2017-01-19
NZ514077A (en) 2004-02-27
JP2013241466A (ja) 2013-12-05
JP2015091834A (ja) 2015-05-14
DK1163349T3 (da) 2008-06-23
CA2365923A1 (en) 2000-09-14
ES2300256T3 (es) 2008-06-16
PL210833B1 (pl) 2012-03-30
EP1163349A2 (en) 2001-12-19
EP2186902A2 (en) 2010-05-19
EP1163349B1 (en) 2008-02-20
CN103585621B (zh) 2016-08-10
NO20014415L (no) 2001-11-12
RU2248213C2 (ru) 2005-03-20
CA2833396C (en) 2018-08-28
CY1107951T1 (el) 2013-09-04
PT2314699T (pt) 2017-08-01
JP2018038423A (ja) 2018-03-15
HUP0200467A2 (en) 2002-06-29
EP1820862A2 (en) 2007-08-22

Similar Documents

Publication Publication Date Title
CY1113051T1 (el) Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
CY1116747T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
CY1110271T1 (el) Υδατικες παρατεταμενης-απελευθερωσης φαρμακοτεχνικες μορφες πρωτεϊνων
CY1108486T1 (el) Μορφες δοσολογιας αζιθρομυκινης με μειωμενες παρενεργειες
CY1108578T1 (el) Φαρμακευτικες συνθεσεις (κιτ) περιλαμβανοντας ενωσεις διϋδροπυριδινονης και εναν ανοσορυθμιστικο (ή εναν αντιφλεγμονωδη) παραγοντα και οι χρησεις αυτων
CY1109786T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
DK1641483T3 (da) Fusionsproteiner
CY1106283T1 (el) Κινολινυλ-πυρρολοπυραζολες
NO20031019L (no) Vedvarende frigivelsesformuleringer av oksymorfon
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
CY1105235T1 (el) Συνθεσεις λασοφοξιφενης
CY1107780T1 (el) Μεθοδος για τη θεραπεια οφθαλμικων νεοαγγειακων ασθενειων
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1108871T1 (el) Υποκατεστημενα παραγωγα αμινο-φουραν-2-υλ-οξεικου οξεος και αμινο-θειεν-2-οξεικου οξεος και η χρησιμοποιηση τους για τη θεραπεια ημικρανιας ή πονου
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743